A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Financial Summary
| Share Statistics | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,722.2 | $250.1 | 59% |
|
| Shares Out (Mil) | 10.8 | 54.0 | 22% |
|
| Institutional Ownership | 49.5% | 93.1% | 23% |
|
| Float (Mil) | 58.3 | 41.4 | 50% |
|
| Beta | 0.59 | 0.95 | 34% |
|
| Avg Daily Volume (000s) | 1 | 661 | 4% |
|
| Price Change (52-week) |
na | 49.5% | na |
|
| Growth | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 114.9% | 12.5% | 99% |
|
| Net Income (5yr) | 56.2% | (10.1%) | 95% |
|
| EPS (5yr) | 42.7% | 15.8% | 90 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 80.8% | (15.7%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $710 | $37 | 45% |
|
| Net Income (TTM) (Mil) | $419 | ($44) | 76% |
|
| EPS (TTM) | $5.950 | ($1.600) | 89% |
|
| Operating Cash Flow (TTM) (Mil) | ($268) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($503) | $2 | 6% |
|
| Long-Term Debt (Q1) (Mil) | $58 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $749 | $175 | 38% |
|
| Valuation | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.36 | na |
|
| P/E | na | 18.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.3% | 96% |
|
| Net Margin | 59.0% | (74.8%) | 98% |
|
| ROA | 14.6% | (47.6%) | 93% |
|
| ROE | 16.1% | (54.9%) | 73% |
|
| Liabilities to Assets | 8.9% | 29.3% | 5% |
|
| F-Score | na | 3 | na |
|
Zealand Pharma A/S did not pass any screens on 10/2/2026.
